Blog

Patrick Hwu: Low Avidity T Cells Drive Cancer Control: A New Insight

Patrick Hwu/X

Jan 20, 2025, 20:02

Patrick Hwu: Low Avidity T Cells Drive Cancer Control: A New Insight

Patrick Hwu, President and CEO at Moffitt Cancer Center, posted the following on LinkedIn:

“T cells recognize tumors through binding of their T-cell receptors (TCRs) to peptide antigens within MHC molecules.

What is the optimal strength of this receptor binding, known as ‘avidity,’ to mediate antitumor immunity?

In this work from the Srivastava Lab, low avidity T cells were found to drive cancer control, while high-affinity T cells were associated with T cell exhaustion.

This interesting (and unintuitive) insight may help guide future immunotherapy design.”

Read the full study

Low-avidity T cells drive endogenous tumor immunity in mice and humans

Authors: Summit Singhaviranon, Joseph P. Dempsey, Adam T. Hagymasi, Ion I. Mandoiu & Pramod K. Srivastava

Patrick Hwu: Low Avidity T Cells Drive Cancer Control: A New Insight

Adam T. Hagymasi avidity cancer immunotherapy Ion I. Mandoiu Joseph P. Dempsey Nature Magazine OncoDaily oncology research Patrick Hwu Pramod K. Srivastava Srivastava Lab Summit Singhaviranon T cells University of Connecticut Health Center

Does Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Miranda McKeon: Battling Breast Cancer at 19, Inspiring Millions on Instagram